In the past decades, there was an improvement in survival in the pediatric heart transplantation. Despite advances in immunosuppression therapy and the pharmacogenetics of these patients, the lymphoproliferative disease still remains as a limiting factor in survival. There are few studies evaluating the lymphoproliferative disease and the risk factors associated with this condition which has motivated us to perform the research. The objective of this study is to analyze the clinical symptoms and signs of lymphoproliferative disease and its potential risk factors. The study is a cohort and will include historical information contained in records relating to the presence of lymphoproliferative disease in patients who were submitted to heart transplantation at the Heart Institute (InCor) HC-FMUSP. The data collected will be cytomegalovirus infection, ischemia time, reactive panel antibody, blood type, age and gender of the recipient; age, gender and blood group type of donor, Epstein-Barr virus serology and the relationship with the clinical outcome of these patients will be analyzed.
News published in Agência FAPESP Newsletter about the scholarship: